Clostridium Difficile Associated Disease Clinical Trial
Official title:
A PHASE 2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TWO 3-DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS
This study will investigate a Clostridium difficile vaccine in healthy adults aged 65-85 years. Each subject will initially receive 3 doses of vaccine on 1 of 2 vaccination schedules. The study will assess the safety and tolerability of the vaccine as well as the subjects' immune response to the vaccine. One year after the third dose subjects that did not receive placebo will be randomized to receive a fourth dose. Subjects will be followed for up to 4 years after their third vaccination.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01706367 -
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
|
Phase 1 | |
| Completed |
NCT03579459 -
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
|
Phase 3 | |
| Active, not recruiting |
NCT02117570 -
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
|
Phase 2 | |
| Completed |
NCT02725437 -
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
|
Phase 1 | |
| Completed |
NCT03918629 -
Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
|
Phase 3 |